New drug cocktail aims to shrink head and neck tumors before surgery
NCT ID NCT07550972
First seen Apr 28, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This study tests whether combining two drugs, pertuzumab and lenvatinib, can shrink advanced head and neck cancers before surgery. About 30 adults with newly diagnosed, locally advanced squamous cell carcinoma will receive the drug combination before their operation. The goal is to see if this approach improves the chance of eliminating the tumor completely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.